Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:33 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 11,325 matching trials from the live ClinicalTrials.gov search.
Filters: Cleveland, Ohio Clear all
Not listed Not applicable Interventional

CPAP Adherence Pilot Study Among African Americans

NCT05955287
View directory record Official record
Conditions
Sleep Apnea
Interventions
Telemonitoring, Peer Based, CPAP Education, Usual Care
Behavioral
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 4 Interventional Results available

Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery

NCT02969187
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Exparel, Bupivacain, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Nov 3, 2026, 4:33 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 3 Interventional Results available

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

NCT01802333
View directory record Official record
Conditions
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride, Idarubicin, Laboratory Biomarker Analysis, Vorinostat
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
441
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 302 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Nov 3, 2026, 4:33 AM EST
Not listed No phase listed Observational

TruGraf® Long-term Clinical Outcomes Study

NCT04491552
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Patients monitored with TruGraf and TRAC testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
36
States / cities
Tucson, Arizona • Fresno, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 3, 2026, 4:33 AM EST
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Nov 3, 2026, 4:33 AM EST
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Nov 3, 2026, 4:33 AM EST
Completed No phase listed Observational

DF4 Connector System Post-Approval Study

NCT01638897
View directory record Official record
Conditions
Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Nov 3, 2026, 4:33 AM EST
Recruiting No phase listed Observational

Observational PIC Destination Cohort

NCT05985642
View directory record Official record
Conditions
HIV-1-infection
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
San Francisco, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 3, 2026, 4:33 AM EST
Completed Not applicable Interventional Results available

Use of Real Time Instrumentation (RTI) in Total Shoulder Arthroplasty

NCT01905241
View directory record Official record
Conditions
Anatomic Total Shoulder Arthroplasty
Interventions
Anatomic TSA using RTI, Anatomic Total Shoulder Arthroplasty
Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

NCT05832151
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mg, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
100
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 1 Interventional

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

NCT00813969
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Nov 3, 2026, 4:33 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nourish Clinical Trial

NCT06947954
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
Nourish intervention then no intervention, no intervention then Nourish intervention
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 3 Interventional Results available

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

NCT00548405
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
85
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 3 Interventional Results available

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)

NCT01502956
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
InterStim® device, Botox® injection
Device · Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Nov 3, 2026, 4:33 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 4:33 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Reduction During Intrauterine Device (IUD) Insertion in Outpatient Gynecology

NCT06335823
View directory record Official record
Conditions
IUD Insertion Pain
Interventions
Transcutaneous electrical nerve stimulation (TENS), Placebo Transcutaneous electrical nerve stimulation (TENS)
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 2 Interventional

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

NCT02048059
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Anti-Influenza Immune Plasma, Standard Care
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
35
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Nov 3, 2026, 4:33 AM EST
Completed No phase listed Observational Results available

SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients

NCT00940888
View directory record Official record
Conditions
Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
Interventions
SJ4 connector and RV high voltage SJ4 lead
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

NCT00002888
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Nov 3, 2026, 4:33 AM EST
Completed No phase listed Observational

Comparative Study of Anterior vs. Posterior Surgical Treatment for Lumbar Isthmic Spondylolisthesis

NCT02564705
View directory record Official record
Conditions
Isthmic Spondylolisthesis
Interventions
Anterior Lumbar Interbody Fusion (ALIF), Posterior Fusion
Procedure
Lead sponsor
AOSpine North America Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
San Francisco, California • Urbana, Illinois • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 3, 2026, 4:33 AM EST
Completed Phase 3 Interventional Results available

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo, Secukinumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Nov 3, 2026, 4:33 AM EST
Recruiting Phase 3 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo-Matching Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 4:33 AM EST